- Home
- FREY vs VRCA Comparison
FREY vs VRCA Comparison
Compare FREY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- VRCA
- Stock Information
- Founded
- FREY 2018
- VRCA 2013
- Country
- FREY Luxembourg
- VRCA United States
- Employees
- FREY N/A
- VRCA N/A
- Industry
- FREY Industrial Machinery/Components
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- FREY Miscellaneous
- VRCA Health Care
- Exchange
- FREY Nasdaq
- VRCA Nasdaq
- Market Cap
- FREY 154.4M
- VRCA 363.1M
- IPO Year
- FREY N/A
- VRCA 2018
- Fundamental
- Price
- FREY $1.02
- VRCA $1.46
- Analyst Decision
- FREY Hold
- VRCA Buy
- Analyst Count
- FREY 4
- VRCA 5
- Target Price
- FREY $1.95
- VRCA $11.75
- AVG Volume (30 Days)
- FREY 1.3M
- VRCA 1.2M
- Earning Date
- FREY 11-07-2024
- VRCA 11-07-2024
- Dividend Yield
- FREY N/A
- VRCA N/A
- EPS Growth
- FREY N/A
- VRCA N/A
- EPS
- FREY N/A
- VRCA N/A
- Revenue
- FREY N/A
- VRCA $13,908,000.00
- Revenue This Year
- FREY N/A
- VRCA $343.03
- Revenue Next Year
- FREY $414.23
- VRCA $151.61
- P/E Ratio
- FREY N/A
- VRCA N/A
- Revenue Growth
- FREY N/A
- VRCA 61.61
- 52 Week Low
- FREY $0.91
- VRCA $1.04
- 52 Week High
- FREY $3.88
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- FREY 47.31
- VRCA 39.17
- Support Level
- FREY $0.99
- VRCA $1.22
- Resistance Level
- FREY $1.04
- VRCA $1.66
- Average True Range (ATR)
- FREY 0.06
- VRCA 0.19
- MACD
- FREY 0.02
- VRCA 0.09
- Stochastic Oscillator
- FREY 50.58
- VRCA 65.63
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.